Decrease RTR, IR, and CR Due to Dissolution Deficiencies (21of28) GDF – Apr. 3-4, 2019
25:40
Impurity Case Studies: Pharmacology/Toxicology (22of28) Generic Drugs Forum – Apr. 3-4, 2019
2:35:24
An In-Depth Look at the Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs
1:56:59
Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA
4:07:45
FDA Clinical Investigator Training Course (CITC) 2024 (Day 3 of 3)
1:57:53
Clinical Pharmacology Considerations for Novel Therapeutic Modalities
2:47:58
FDA FY2025 Small Business Fair
1:57:16
M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms - Implementing the Final Guidance
15:23